Results 121 to 130 of about 1,013,786 (315)

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report [PDF]

, 2008
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO ...
Morrissey, John R., Bhattacharya Sayantan, Morrissey John, Choudhury Amit, Bhattacharya, Sayantan, Ravi, Srinivasan, Mathew, G. (George), Ravi Srinivasan, Mathew George, Choudhury, Amit Kumar   +9 more
core   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Berking, Carola, Bockmeyer, Clemens L., Voskens, Caroline J., Fluck, Michael, Heinzerling, Lucie M., Schuler, Gerold, Vaubel, Julia, Keller, Ullrich, Goldinger, Simone M., Wilhelm, Tabea, Moos, Roger von, Mohr, Peter, Eigentler, Thomas, Paetzold, Sylvie, Justich, Armin, Hundorfean, Gheorghe, Hauschild, Axel, Mateus, Christine, Klein, Christina, Loquai, Carmen, Schadendorf, Dirk, Göppner, Daniela, Robert, Caroline, Bergmann, Tanja, Gutzmer, Ralf, Hein, Rüdiger, Grabbe, Stephan, Dummer, Reinhard, Kaehler, Katharina C., Trefzer, Uwe, Ulrich, Jens, Weder, Patrik, Schuler-Thurner, Beatrice, Garbe, Claus, Satzger, Imke, Schlaeppi, Marc   +35 more
core   +1 more source

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel

Dermatology Practical & Conceptual, 2023
Chryssoula Papageorgiou, Zoe Apalla, Eleni Timotheadou, Konstantia Loga, Elizabeth Lazaridou, Dimitrios Dionysopoulos   +5 more
doaj   +1 more source

Metastatic chordoma [PDF]

JAAD Case Reports, 2019
Suarez Conde, María Florencia, Vallone, Maria Gabriela, González, Virginia Mariana, Vigovich, Felix Alberto, Casas, Jose Gabriel, Cermignan, Luciano, Bas, Carlos Arturo, Larralde, Margarita   +7 more
openaire   +2 more sources

Metastatic melanoma [PDF]

CA: A Cancer Journal for Clinicians, 2020
Ragini R, Kudchadkar, Michael C, Lowe, Mohammad K, Khan, Stephanie M, McBrien   +3 more
openaire   +2 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source